3 1. Framing the problem 2. Some T Basic Science & Saturation Theory 3. BPH LUTS & T The Data 4. Prostate Cancer (CAP & T) The Data Low testosterone as a risk factor for prostate cancer TTh in men with a history of prostate cancer TTh in men with untreated prostate cancer
4 Multinational physician survey on testosterone therapy Most common physician concern is prostate cancer risk Brazil Saudi Arabia South Korea Germany Spain United Kingdom BPH, benign prostatic hyperplasia. Reproduced from Gooren LJ et al. Aging Male. 2007;10(4): Concerns Rated Very Important
5 Patients with BPH treated with androgens are at an increased risk for worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms. Contraindication: Men with carcinoma of the breast or known or suspected prostate cancer. AndroGel 1.62% Product Insert. North Chicago, IL: AbbVie Inc.
6 Increases in testosterone make CAP worse. High T increases DHT and thus increase prostate size. Lower testosterone levels decrease CAP risk and LUTS risk (as prostate get smaller).
7 Blocking DHT leads to decreased prostate growth by about 25%* The MTOPS trial demonstrated this quite well and as a result finasteride and other 5-ARi s are a mainstay for symptomatic treatment of BPH. It is the only drug to definitively decrease retention and need for prostate surgery. *Kaplan et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostatic sizes in men enrolled in the MTOPS trial. J Urol. 2008;180(3):1030-2
8 St Sauver JL, et al. Association between longitudinal and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J Urol. 2010;184(3): Moore A, et al. Testosterone Replacement Therapy on the natural History of Prostate Disease. Curr Urol Rep. 2015;16(8):526.
9 LOH symptom severity increases with increasing LUTS scores. LUTS, lower urinary tract symptoms; SLOH, symptomatic late-onset hypogonadism. Bozkurt, O., et al. (2013). "Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly men." Asian J Androl 15(6):
10 Low T = low PSA Little change in PSA with T Saturation point = 8nmol ~ 250ng/dl Morgentaler, A. and W. P. Conners (2015). "Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations." Asian J Androl 2015;17(2):
11 Hypogonadism can be considered a Proinflammatory state Chronic inflammation and its effect on LUTS/BPH is seen in conjunction with low testosterone 1. Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Current urology reports. 2014;15(12): Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. The Journal of endocrinology. 2012;214(1):31-43
12 In vitro cell lines demonstrate increased CD8+ T Cells in finasteride BPH cells More than 60% of CD8+ T from blood of health persons migrated to the prostate tissue lysates from the finasteride group - (64.02% versus 10.31%) Molt-3 = T lymphocyte cell line Fan Y, et al. Low Intraprostatic DHT promotesthe Infiltration of CD8+ Tcells in BPH Tissues via Modulation of CCL5Secretion. Mediators of Inflammation 2014;2014:397875
13 BPH Control Tissue Finasteride BPH Tissue Fan Y, et al. Low Intraprostatic DHT promotes the Infiltration of CD8+ T cells in BPH Tissues via Modulation of CCL5Secretion. Mediators of Inflammation 2014;2014:397875
14 Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. The Journal of endocrinology. 2012;214(1):31-43
15 Moore A, et al. Testosterone Replacement Therapy on the natural History of Prostate Disease. Curr Urol Rep. 2015;16(8):526.
16 Delay, UCNA 2016
17 Systematic Review and Meta-analysis 14 trials of 2029pt, with mean age of 64.5 y/o with LOH Forest Plot of IPSS score with men on TRT vs Placebo TRT does not worsen LUTS in men with LOH Kohn T, et al. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. Eur Urol 2016; Feb 10 epub ahead of print.
18 340 men with measurements of Bio-T, E2, DHT, DHEA followed longitudinally for LUTS symptoms to appear Higher Mid-life DHT = less LUTS/BPH 1 Higher T levels inversely proportional to rate of LUTS/BPH point improvement of IPSS while on T 5 After controlling for confounders, data from the CUPID study showed only predictors of low T in cardiac population were age, BMI and irritative symptoms 1. Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. The Journal of urology. 2010;184(3): St Sauver JL, Jacobson DJ, McGree ME, Girman CJ, Klee GG, Lieber MM et al. Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes. American journal of epidemiology. 2011;173(7): Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. American journal of epidemiology. 2008;168(12): Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU international. 2007;100(2): Pearl JA, Berhanu D, Francois N, Masson P, Zargaroff S, Cashy J et al. Testosterone supplementation does not worsen lower urinary tract symptoms. The Journal of urology. 2013;190(5):
20 Number of articles showing testosterone therapy causes prostate cancer in PSA era None!
21 Effect of TTh on Normal Prostate Tissue?
22 Effects of TTh on Prostate Tissue of Aging Men with Low Serum T R, DB, PC trial of 44 men (44-78 years) Inclusion criteria: T < 300 ng/dl Symptoms of hypogonadism Randomly assigned to receive 150 mg TE or placebo q 2 weeks X 6 months 12-core TRUS prostate biopsies were performed at baseline and 6 months Primary outcomes: 6-month change in prostate T & DHT Marks L, et al, JAMA, 296:2351, 2006.
23 Effects of TTh on Prostate Tissue of Aging Men with Low Serum T ng/g Prostatic Tissue Testosterone DHT Baseline 6 Months Baseline 6 Months TRT (n=21) Placebo (n=19)
24 If one assumes that higher testosterone levels increase the risk for prostate cancer, then are lower testosterone levels considered protective against the development of prostate cancer?
25 Low Testosterone Associated with Increased Risk of Prostate Cancer Isom-Batz,et al. J Urol. 2005; 173: Lower testosterone correlated with higher: Pathological stage Clinical stage Biopsy Gleason grade Teloken, et al. J Urol. 2005; 174: Lower testosterone correlated with: Increased positive surgical margins 39% in low TT vs 14.6% in normal TT Schatzl, et al. J Urol. 2003; 169: Lower testosterone correlated with: Higher tumor density Higher Gleason score
26 No History of Prostate Cancer High Risk (High Grade P.I.N.) TTh and Risk for Prostate Cancer Treated Prostate Cancer Radiation Radical Prostatectomy
27 Global Pooled Longitudinal Study of Hormones and PCa Risk 3886 men with PCa 6448 age-matched controls No significant relationship between androgens and PCa Endogenous Hormones and Prostate Cancer Collaborative Group. J Natl Cancer Inst. 2008;100(3):
28 No History of Prostate Cancer High Risk (High Grade P.I.N.) TTh and Risk for Prostate Cancer Treated Prostate Cancer Radiation Radical Prostatectomy
29 High Risk (HGPIN) 75 hypogonadal men treated with TTh for 12 months All men underwent prostate biopsy prior to TTh 55 men had benign biopsies (-PIN) 20 men with PIN (+PIN) Results No significant change in PSA in either group One patient in +PIN group found to have prostate cancer on biopsy after abnormal DRE Conclusion: After 1 year of TTh, men with PIN did not have a greater increase in PSA or a significant increased risk of cancer than men without PIN Rhoden EL, Morgentaler A, J Urol 170: , 2003
30 No History of Prostate Cancer High Risk (High Grade P.I.N.) TTh and Risk for Prostate Cancer Treated Prostate Cancer Radiation Radical Prostatectomy
31 98 hypogonadal men treated with TTh after XRT or brachytherapy Gleason 5 (3.1%), 6 (44.9%), 7 (28.6%), 8 (7.1%) and 9 (4.1%) Median follow-up 40.8 months Results T increased from 209 ng/dl to 420 ng/dl PSA change from 0.08 ng/ml to 0.09 ng/ml Among high risk patients, PSA increased from 0.10ng/dl to 0.36ng/dl Six (6.1%) men met criteria for biochemical recurrence Pastuszak et al. J Urol Nov;194(5):1271-6
32 Retrospective review of 103 hypogonadal men treated with TTh after RP between and 49 eugonadal controls having undergone RP treated during this time High Risk CaP - post-surgical pathology with one or more of the following: 1) Gleason score 8, 2) positive surgical margins, or 3) positive lymph nodes TTh Group - 77 men with low/intermediate risk CaP (non-high risk) and 26 with high-risk CaP Control Group 34 men non-high risk and 15 men high-risk CaP Results: 12 biochemical recurrences ONLY in high risk patients after 36 months 4 biochemical recurrence in TTh group (15.3%) 8 biochemical recurrences in control (non-tth group) (53.3%) Pastuszak et al J Urol Aug;190(2):639-44
33 TTh after Prostate Cancer A total of 9 published studies thus far have provided information on TTh after treatment for prostate cancer (RP, brachytherapy, EBRT) Total of 346 patients given TTh after treatment for their prostate cancer Only 10 men, or 2.8 % of men, were noted to have a biochemical recurrence Recurrence rate is less than published series in favorable groups² TTh protective? ¹Morgentaler J Urol 2009; 181:972 ²van Oort et al. Urol Oncol 2008 Epub
34 TTh and Prostate Cancer Cell Suppression Hatzoglou et al- membrane androgen receptor activation induced apoptotic regression of human prostate cancer cells in vitro and in vivo¹ Sonnenschein et al. - androgens were able to trigger an inhibition of prostate cancer cell proliferation at higher concentration² Chuu et al. - androgens caused growth suppression and then reversion of androgen independent tumors to an androgen dependent tumors³ ¹ Hatzoglou et al J Clin Endocrinol Metab 2005, 90: ²Sonnenschein et al. Cancer Res 1989, 49: ³Chcuu et al Cancer Res 2005, 65:2082-4
36 Sci Transl Med.2015 Jan 7;7(269): 14 patients with CRPC TE 400mg IM q month for 3 months Castrating therapy continued to suppress endogenous testosterone production, allowing for rapid cycling from supraphysiologic to near-castrate serum testosterone levels = bipolar androgen therapy (BAT) BAT was well tolerated and resulted in high rates of PSA (7 of 14 evaluable patients) and radiographic responses (5 of 10 evaluable patients)
37 What about Active Surveillance?
38 28 hypogonadal men on AS and TTh for at least 6 months Control: 96 hypogonadal men on AS and not receiving TTh Follow-up 38.9 and 42.4 months T and non-t group, respectively Non-T group (n=96): All men with GL (44.7%) developed biopsy progression, including 9 men (9.38%) with upgrading to Gleason 7 (3 + 4) T group (n=28): 22 men with GL 3+3 and 6 men with GL 3+4 GL 3+3: 7 (31.8%) men developed biopsy progression including 3 men (13.6%) who developed Gleason PCa GL 3+4: 2 (33.3%) men developed an increase in tumor volume, and none developed upgrading beyond Gleason Kacker et al Asian J Androl Jan-Feb;18(1):16-20.
39 154 men were followed with AS for prostate cancer 54 (35%) progressed to active treatment Men who progressed had significantly lower free testosterone levels than those who remained on AS (0.75 vs 1.02 ng/dl, P = 0.03) Free testosterone levels <0.45 ng/dl were associated with a seven-fold increase in the risk of disease progression (OR 4.3, 95% CI ) Multivariate analysis demonstrated that free testosterone and family history of PCa were independent predictors of disease progression San Francisco et al BJU Int Aug;114(2):
40 Khera et al. Eur Urol Jan;65(1):115-23
41 Conclusion While TTh does significantly impact PSA levels and size in hypotrophic prostates (levels of serum testosterone below saturation point), TTh does not appear to affect prostate size, or intra-prostatic testosterone levels in T saturated prostates There is currently no evidence that TTh promotes the initiation of BPH/LUTS or prostate cancer in hypogonadal men Hypogonadal men receiving TTh after history of prostate cancer appear to have low recurrence rates of prostate cancer. Some hypogonadal men who are given TTh have improvement in LUTS.
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
. 11 Mini Reviews UNPREDICTABILITY OF TESTOSTERONE THERAPY MORALES BJUI Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry
How do I control (monitor) patients receiving TRT after prostate cancer treatment Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
European Urology Supplements European Urology Supplements 4 (2005) 16 23 Testosterone Substitution and the Prostate E. David Crawford* University of Colorado Health Sciences Center, 1665 N. Ursula Street,
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
(2015) 17, 206 211 2015 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Male Endocrinology Open Access INVITED REVIEW Testosterone therapy in men with prostate cancer:
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
NEW PERSPECTIVES ON BPH 5- -Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia Claus G. Roehrborn, MD Department of Urology, The University of Texas Southwestern Medical Center
Late Onset Hypogonadism Toh Charng Chee Hospital Selayang Introduction Although suppressed serum testosterone (T) is common in ageing men, only a small proportion of them develop the genuine syndrome of
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
Trends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance Metropolitan Underwriting Discussion Group Annual Meeting January 30, 2017 Prostate Cancer is Common Rudy Giuliani Dx
Testosterone Deficiency in Men Ron Rothenberg MD Relevant financial relationships in the past twelve months by presenter or spouse/partner: NA Equipment: NA Speakers Bureau: NA Stock Shareholder: NA Grant/Research
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.33 Subject: Testosterone Injection Implant Page: 1 of 10 Last Review Date: March 17, 2017 Testosterone
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
Radiation with oral hormonal manipulation for non-metastatic, intermediate or high risk prostate cancer in men 70 and older or with comorbidities Prostate cancer is predominately a disease of older men,
PROSCAR (finasteride 5 mg) Supplemental New Drug Application Prostate Cancer Prevention Trial Oncologic Drugs Advisory Committee Briefing Document Presented to ODAC on 01-December 2010 Available for Public
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
Evaluation and Treatment of Primary Androgen Deficiency Syndrome in Male Patients Jeff Unger, MD Director Chino Medical Group Diabetes and Headache Intervention Center Chino, California January 16, 2008
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
Quality of Life after Treatment of Localised Prostate Cancer Dr Jeremy Grummet Clinical Uro-Oncology Fellow May 28, 2008 1 Why? This is important May be viewed as soft science Until we know which treatment
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.37 Subject: Testosterone Powder Page: 1 of 11 Last Review Date: September 18, 2015 Testosterone powder
4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant
European Urology European Urology 43 (2003) 528 534 DrugTreatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related Surgery P.C. Souverein a,*, J.A. Erkens b, J.J.M.C.H. de la Rosette
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
Late onset Hypogonadism Dr KhooSay Chuan Department of Urology Penang General Hospital Late onset hypogonadism(loh) Definition LOH age associated testoteronedeficiency syndrome (TDS) Male menopause, andropause,
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
Prostate Cancer CEUS of the Prostate 2017 Data Incidence: 161,360 Deaths: 26,730 Third leading cause of cancer death in men (after lung & Professor of Radiology & Urology colon Ca) Co-Director, Jefferson
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
European Urology European Urology 44 (2003) 461 466 Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride J.
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
Date of preparation- January 2018 Janssen Biotech, Inc. 2018 02/18 em-01856 Reporter s guide to prostate cancer What is the prostate? The prostate is a gland located below the bladder, wrapped around the
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
(2016) 18, 54 59 2016 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Prostate Disease Open Access ORIGINAL ARTICLE Effect of serum testosterone and percent tumor
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
Testosterone Replacement Therapy & Monitoring in HIV Infected Men Adam B. Murphy, MD, MBA, MSCI October 29, 2014 Acknowledgement Ramona Bhatia MD (HIV Research Fellow, First Author) Chad Achenbach MD (HIV
european urology supplements 5 (2006) 752 757 available at www.sciencedirect.com journal homepage: www.europeanurology.com Do 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?
Brian D. Kavanagh, MD, MPH Department of Radiation Oncology University of Colorado Contemporary Radiation Therapy Options for Prostate Cancer Case study: RT for early stage prostate cancer A 67-year-old
Prostate Cancer Case Study 2 Medical Student Case-Based Learning The Case of Mr. Powers Prostate Cancer Recurrence Mr. Powers is a young appearing, healthy 73-year old male who underwent a radical prostatectomy
European Urology Supplements European Urology Supplements 2 (23) 2 7 The Hallmarks of BPH Progression and Risk Factors M. Emberton * Institute of Urology and Nephrology, University College London, 48 Riding
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives
PROSTATE CANCER (PCa) Tomasz Drewa Department of Urology, Collegium Medicum, UMK ? PCa = 11/6/16 PCa Urology, 1995 11/6/16 PSA increase Natural history of prostate cancer patient Testosterone Deprywacja
MOLECULAR AND CLINICAL ONCOLOGY 2: 1145-1149 Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy CAROLINA D'ELIA, MARIA ANGELA CERRUTO, ANTONIO CIOFFI, GIOVANNI NOVELLA,
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC 9420 Key West Ave, Suite 420, Rockville, MD 20850 2730 University Blvd, West, Suite 516, Wheaton,
PROSTATE CANCER Mr. Jawad Islam MBBS, MSc, FRCS(Ed), FEBU, FRCS(Urology) Consultant Urologist Where is prostate located and what is its function? What is prostate cancer? How common is prostate cancer?
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation Alice Dragomir, PhD Fabio Cury, MD Armen Aprikian, MD Introduction Clinical and economic burden
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai